Biogen Partners with Alloy Therapeutics for Multi-Target Antisense Drug Development
BIIB sits 57% above its 52-week low of $110.035.
Summary
Biogen has entered into a multi-target collaboration and license agreement with Alloy Therapeutics, leveraging Alloy's Anticlastic™ ASO platform to advance antisense therapeutics against multiple undisclosed targets. This strategic partnership expands Biogen's research and development capabilities in a key therapeutic area. This collaboration follows a period of significant activity for Biogen, including a major acquisition and several positive drug development announcements. While specific financial terms were not disclosed, this agreement represents a positive step in Biogen's strategy to diversify and strengthen its drug development pipeline. Traders will monitor for future updates on specific targets and development milestones.
At the time of this announcement, BIIB was trading at $172.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.3B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.